SGLT-2 Inhibitors and Dementia Prevention
Author Information
Author(s): Hung Cheng-Hsien, Lu Li-Yu
Primary Institution: Chang Bing Show Chwan Memorial Hospital
Hypothesis
Can SGLT-2 inhibitors reduce the risk of dementia in patients with type 2 diabetes?
Conclusion
SGLT-2 inhibitors may help lower the risk of dementia and improve cognitive function in type 2 diabetes patients.
Supporting Evidence
- SGLT-2 inhibitors are linked to a lower risk of dementia in diabetic patients.
- Meta-analyses show a pooled hazard ratio of 0.68 for dementia incidence among SGLT-2 inhibitor users.
- Real-world studies support the findings of clinical trials regarding dementia risk reduction.
Takeaway
SGLT-2 inhibitors are medicines that help people with diabetes and might also protect their brains from dementia.
Methodology
This review summarizes existing research on the effects of SGLT-2 inhibitors on dementia risk.
Potential Biases
Potential biases due to varying study designs and populations.
Limitations
Many studies have small sample sizes and short follow-up periods.
Participant Demographics
Participants primarily included individuals with type 2 diabetes.
Statistical Information
P-Value
0.68
Confidence Interval
0.50–0.92
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website